» Articles » PMID: 23401079

Circulating MicroRNA Expression Profiles Associated with Systemic Lupus Erythematosus

Overview
Journal Arthritis Rheum
Specialty Rheumatology
Date 2013 Feb 13
PMID 23401079
Citations 111
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To evaluate the specificity of expression patterns of cell-free circulating microRNAs (miRNAs) in systemic lupus erythematosus (SLE).

Methods: Total RNA was purified from plasma, and 45 different specific, mature miRNAs were determined using quantitative reverse transcription-polymerase chain reaction assays. A total of 409 plasma samples were obtained from 364 different patients with SLE, healthy control subjects, and control subjects with other autoimmune diseases. The results in the primary cohort of 62 patients with SLE and 29 healthy control subjects were validated in 2 independent cohorts: a validation cohort comprising 68 patients with SLE and 68 healthy control subjects, and a disease control cohort comprising 20 patients with SLE (19 of whom were from the other validation cohort), 46 healthy control subjects, 38 patients with vasculitis, 18 patients with rheumatoid arthritis, and 20 immunosuppressed patients.

Results: Seven miRNAs were statistically significantly differentially expressed in plasma from patients with SLE. The expression of miRNA-142-3p (miR-142-3p) and miR-181a was increased, and the expression of miR-106a, miR-17, miR-20a, miR-203, and miR-92a was decreased. In addition, the expression of miR-342-3p, miR-223, and miR-20a was significantly decreased in SLE patients with active nephritis. A predictive model for SLE based on 2 or 4 miRNAs differentiated patients with SLE from control subjects (76% accuracy) when validated independently (P < 2 × 10(-9) ). Use of the 4-miRNA model provided highly significant differentiation between the SLE group and disease controls, except for those with vasculitis.

Conclusion: Circulating miRNAs are systematically altered in SLE. A 4-miRNA signature was diagnostic of SLE, and a specific subset of miRNA profiles was associated with nephritis. All of the signature miRNAs target genes in the transforming growth factor β signaling pathways. Other targets include regulation of apoptosis, cytokine-cytokine receptors, T cell development, and cytoskeletal organization. These findings highlight possible dysregulated pathways in SLE and suggest that circulating miRNA patterns distinguish SLE from other immunoinflammatory phenotypes.

Citing Articles

MicroRNA-203 Expression as Potential Biomarker for Lupus Nephritis.

Setyawan Y, Susianti H, Sulistyarti H, Khrisna M, Mayashinta D, Fitri L Int J Nephrol Renovasc Dis. 2025; 18:53-58.

PMID: 39990192 PMC: 11844303. DOI: 10.2147/IJNRD.S485409.


Inhibition of miRNA associated with a disease-specific signature and secreted via extracellular vesicles of systemic lupus erythematosus patients suppresses target organ inflammation in a humanized mouse model.

Young N, Schwarz E, Zeno B, Bruckner S, Mesa R, Jablonski K Front Immunol. 2024; 14:1090177.

PMID: 38939646 PMC: 11208704. DOI: 10.3389/fimmu.2023.1090177.


Plasma microRNA-320c as a Potential Biomarker for the Severity of Knee Osteoarthritis and Regulates cAMP Responsive Element Binding Protein 5 (CREB5) in Chondrocytes.

Zhou R, Zhao L, Wang Q, Cheng Y, Song M, Huang C Dis Markers. 2024; 2024:9936295.

PMID: 38549717 PMC: 10973101. DOI: 10.1155/2024/9936295.


Lactobacillus rhamnosus and Lactobacillus delbrueckii Ameliorate the Expression of miR-125a and miR-146a in Systemic Lupus Erythematosus Patients.

Vahidi Z, Saghi E, Mahmoudi M, Rezaieyazdi Z, Esmaeili S, Zemorshidi F Appl Biochem Biotechnol. 2024; 196(9):6330-6341.

PMID: 38351428 DOI: 10.1007/s12010-023-04827-w.


Circulating miR-320b Contributes to CD4+ T-Cell Proliferation in Systemic Lupus Erythematosus via MAP3K1.

Li Z, Wang R, Wang D, Zhang S, Song H, Ding S J Immunol Res. 2023; 2023:6696967.

PMID: 37928434 PMC: 10622187. DOI: 10.1155/2023/6696967.


References
1.
Somers E, Zhao W, Lewis E, Wang L, Wing J, Sundaram B . Type I interferons are associated with subclinical markers of cardiovascular disease in a cohort of systemic lupus erythematosus patients. PLoS One. 2012; 7(5):e37000. PMC: 3351452. DOI: 10.1371/journal.pone.0037000. View

2.
Lood C, Amisten S, Gullstrand B, Jonsen A, Allhorn M, Truedsson L . Platelet transcriptional profile and protein expression in patients with systemic lupus erythematosus: up-regulation of the type I interferon system is strongly associated with vascular disease. Blood. 2010; 116(11):1951-7. DOI: 10.1182/blood-2010-03-274605. View

3.
Vickers K, Palmisano B, Shoucri B, Shamburek R, Remaley A . MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol. 2011; 13(4):423-33. PMC: 3074610. DOI: 10.1038/ncb2210. View

4.
Chen C, Li L, Lodish H, Bartel D . MicroRNAs modulate hematopoietic lineage differentiation. Science. 2003; 303(5654):83-6. DOI: 10.1126/science.1091903. View

5.
Kazenwadel J, Michael M, Harvey N . Prox1 expression is negatively regulated by miR-181 in endothelial cells. Blood. 2010; 116(13):2395-401. DOI: 10.1182/blood-2009-12-256297. View